-- Bridgepoint to Ask JPMorgan to Advise on Diaverum Future
-- B y   A a r o n   K i r c h f e l d   a n d   N i k l a s   M a g n u s s o n
-- 2013-01-21T16:52:22Z
-- http://www.bloomberg.com/news/2013-01-21/bridgepoint-to-ask-jpmorgan-to-advise-on-diaverum-future.html
Bridgepoint Advisers Ltd., a U.K.
private-equity firm with more than $12 billion in committed
funds, will choose  JPMorgan Chase & Co. (JPM)  to consider Swedish
renal-care provider Diaverum’s future.  Bridgepoint “is close” to completing JPMorgan’s
appointment to look at strategic options for Lund-based Diaverum
for the next 12 months, James Murray, a spokesman for the firm,
said by phone today.  Diaverum provides renal care to more than 20,000 patients
at about 250 clinics in 17 countries, including in  South
America , Australia, Europe and the  Middle East , according to
information on its  website . The company employs 6,900 people and
reported sales of 398 million euros ($530 million) in 2011.
 Companies owned by  London-based Bridgepoint employ 72,000 people
in more than 40 countries, according to its website.  To contact the reporters on this story:
Aaron Kirchfeld in London at 
 akirchfeld@bloomberg.net ;
Niklas Magnusson in Stockholm at 
 nmagnusson1@bloomberg.net   To contact the editor responsible for this story:
Frank Connelly at 
 fconnelly@bloomberg.net  